annual report 2011-2012 11

FIP has adopted as one of its three main Strategic Objectives to

advance pharmacy practice in all settings. This ambitious goal is

done through the work of the nine Pharmacy Practice Sections,

which develop projects and initiatives to aid FIP and its Member

Organisations truly advance pharmacy practice on a global level.

Throughout this past year, the Board of Pharmaceutical Practice

(BPP) has continued to focus on its strategic and tactical

directions as health care systems, scientific discovery and

innovation and the evolution of pharmacy practice change.

Each of the BPP Sections has worked to align their directions

with the adopted BPP Strategic Plan and the FIPs Vision 2020.

This work will continue as a focus on the future of FIP becomes

clearer and more focused.

For more information on the work of each BPP Section please

click their titles below:

Academic Pharmacy Clinical Biology Community Pharmacy Hospital Pharmacy Industrial Pharmacy Laboratories and Medicines Control Military and Emergency Pharmacy Pharmacy Information Social and Administrative Pharmacy BPP has also worked with the Young Pharmacists Group (YPG)

Strong collaboration continues between the BPP and the Board

of Pharmaceutical Science. Building on discussions held between

the two boards executive committees, several areas have been

identified where collaboration is necessary; these include, pharmacovigilance/pharmacoepidemiology, pharmaceutical

waste/ecology, applied social and behavorial sciences and

nuclear pharmacy. The two Boards are presently exploring the

establishment of a joint working group on pharmaceuticals and

the environment. The latter is a broad and complex subject that

is gaining greater national and international attention. The two

Boards need to determine what the scope of our priorities and

interests should be on this subject.

Extensive discussions have been held by the BPP on the

evolving ethics, professionalism and autonomy issues facing

individual pharmacists in pharmacy practice. Increased focus by

governments on market­based economies, global competitive

forces and cost­containment in the health care sector have the

capacity to compromise these important components of profes­

sional life. A Working Group, co­chaired by Dr. William Zellmer

and Dr. Betty Char, has been appointed to study these issues

and to issue a preliminary report of findings at the 2013 Dublin

Congress.

Board members Jacqueline Surugue and Dominique Jordan have

been requested to do further investigation of new and innova­

tive economic models for pharmacist services reimbursement